# Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

> **NCT02073838** · PHASE2 · COMPLETED · sponsor: **Sarit Assouline** · enrollment: 23 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** Vismodegib
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT02073838
- **Lead sponsor:** Sarit Assouline
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2022-11
- **Final completion:** 2022-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073838, "Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02073838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*